Biophytis S.A. (BPTSY)
OTCMKTS: BPTSY · Delayed Price · USD
6.29
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market open
Biophytis Employees
Biophytis had 22 employees as of December 31, 2023. The number of employees decreased by 2 or -8.33% compared to the previous year.
Employees
22
Change (1Y)
-2
Growth (1Y)
-8.33%
Revenue / Employee
n/a
Profits / Employee
-$859,899
Market Cap
3.01M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
Danaher | 63,000 |
BPTSY News
- 11 days ago - Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity - Accesswire
- 21 days ago - Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris - Accesswire
- 4 weeks ago - Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million - Accesswire
- 4 weeks ago - Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities - Accesswire
- 5 weeks ago - Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens - Accesswire
- 6 weeks ago - Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity - Accesswire
- 2 months ago - Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity - Accesswire
- 3 months ago - Biophytis is Deploying its Partnership Strategy in Obesity - Accesswire